Compare Charles River Laboratories Intl. Inc (CRL) vs Direxion Daily CSI China Internet Bull 2X Shares (CWEB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Direxion Daily CSI China Internet Bull 2X Shares — how do they compare? Charles River Laboratories Intl. Inc trades at $282.01 (market cap $13.22B), while Direxion Daily CSI China Internet Bull 2X Shares trades at $24.55. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Direxion Daily CSI China Internet Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| CRL | CWEB | |
|---|---|---|
Market Cap | $13.22B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.00 | $60.13 |
52-Week Low | $145.57 | $17.70 |
Enterprise Value | $16.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $267.49, up 0.75% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.02 versus $2.77 expected, and raised full-year guidance. Despite negative net income margins and high valuation multiples, analyst sentiment remains overwhelmingly positive with 72% buy ratings.
CRL shows operational strength with consistent earnings beats and improved demand, yet faces risks from high debt and profitability challenges. The consensus price target of $277.29 suggests modest upside, but investors must weigh growth prospects against valuation concerns and macroeconomic pressures on biotech spending.
CWEB trades at $25.53, up 1.67% today, with a bullish technical signal from moving averages. The stock shows strong momentum indicators but an overbought short-term RSI. A dividend of $0.09 is scheduled for June 2026, reflecting potential income return. Recent news highlights renewed interest in China growth stocks, which may benefit CWEB's positioning.
The outlook for CWEB is cautiously optimistic, driven by positive technical trends and sector sentiment. Key risks include reliance on China market dynamics and potential volatility. Investment opportunity lies in growth stock resurgence, but investors must weigh macroeconomic and regulatory uncertainties in the region.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Direxion Daily CSI China Internet Bull 2X Shares
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →
